In 2024, Pfizer and AbbVie retained their positions as the largest pharma companies despite significant revenue declines. Meanwhile, the top 20 saw several notable shifts. This in-depth review details the full list of the industry’s 100 largest pharmaceutical and biotech companies by 2023 sales as reported in 2024.
Top 20 Pharma Companies of 2024
In 2024, several notable shifts occurred in the top 20 pharmaceutical rankings. While the top 5 remained relatively unchanged with Pfizer, AbbVie, and Merck & Co taking the top 3, Johnson & Johnson overtook Roche to secure 4th place. There were also clear winners, including Novo Nordisk and Eli Lilly, both of which saw significant growth in their year-on-year sales.
The full top 20 pharma and biotech companies ranked by 2023 pharmaceutical sales can be seen below, or for a comprehensive overview of the future pharmaceutical industry read out Outlook 2025 report by taking a 1-week free trial to In Vivo.
(1) Pfizer – United States ($58,496m sales)
(2) AbbVie – United States ($53,842m sales)
(3) Merck & Co – United States ($53,583m sales)
(4) Johnson & Johnson – United States ($53,267m sales)
(5) Roche – Switzerland ($50,491m sales)
(6) Novartis – Switzerland ($50,228m sales)
(7) Bristol Myers Squibb – United States ($45,440m sales)
(8) AstraZeneca – United Kingdom ($45,417m sales)
(9) Sanofi – France ($43,789m sales)
(10) GSK – United Kingdom ($42,998m sales)
(11) Eli Lilly – United States ($40,985m sales)
(12) Novo Nordisk – Denmark ($37,724m sales)
(13) Takeda – Japan ($34,124m sales)
(14) Amgen – United States ($33,722m sales)
(15) Gilead Sciences – United States ($30,363m sales)
(16) Boehringer Ingelheim – Germany ($29,482m sales)
(17) Teva Pharmaceutical – Israel ($28,190m sales)
(18) Viatris – United States ($27,281m sales)
(19) Bayer – Germany ($27,116m sales)
(20) CSL – Australia ($26,323m sales)
Pharmaceutical revenues in the top 100 are based on data from Evaluate Pharma and exclude licensing revenues and royalty streams.
Complete List of the Top 100 Pharma and Biotech Companies of 2024
The following section provides a complete ranking of pharmaceutical and biotech companies placed 21 to 100, offering insight into their performance and positioning within the industry.
For a more comprehensive analysis of the companies in the top 100 pharma rankings take a 1-week free trial to In Vivo.
Top Pharma and Biotech Companies Ranked 21-50
(21) Astellas Pharma – Japan ($11,108m sales)
(22) Daiichi Sankyo – Japan ($10,027m sales)
(23) Vertex Pharmaceuticals – United States ($9,869m sales)
(24) Otsuka Holdings – Japan ($9,707m sales)
(25) Sandoz Group – Switzerland ($9,647m sales)
(26) Merck KGaA – Germany ($8,711m sales)
(27) Bausch Health Companies – Canada ($8,638m sales)
(28) Biogen – United States ($7,247m sales)
(29) Regeneron Pharmaceuticals – United States ($7,078m sales)
(30) Moderna – United States ($6,671m sales)
(31) Organon – United States ($6,099m sales)
(32) Grifols – Spain ($6,012m sales)
(33) Sun Pharmaceutical Industries – India ($5,749m sales)
(34) UCB – Belgium ($5,681m sales)
(35) Abbott Laboratories – United States ($5,039m sales)
(36) Eisai – Japan ($4,590m sales)
(37) Fresenius – Germany ($4,538m sales)
(38) STADA Arzneimittel – Germany ($3,795m sales)
(39) Jazz Pharmaceuticals – Ireland ($3,737m sales)
(40) Shanghai Pharmaceutical Group – China ($3,711m sales)
(41) CSPC Pharmaceutical Group – South Korea ($3,597m sales)
(42) Sino Biopharmaceutical – Hong Kong ($3,565m sales)
(43) Ono Pharmaceutical – Japan ($3,482m sales)
(44) Ipsen – France ($3,413m sales)
(45) Aurobindo Pharma – India ($3,409m sales)
(46) Chiesi – Italy ($3,273m sales)
(47) Dr. Reddy’s Laboratories – India ($3,233m sales)
(48) Incyte – United States ($3,165m sales)
(49) Kyowa Kirin – Japan ($3,154m sales)
(50) Mitsubishi Chemical – Japan ($3,118m sales)
Top Pharma and Biotech Companies Ranked 51-100
(51) Jiangsu Hengrui Pharmaceuticals – China ($3,112m sales)
(52) Sichuan Kelun Pharmaceutical – China ($3,032m sales)
(53) Perrigo Company – Ireland ($2,962m sales)
(54) Hikma Pharmaceuticals – United Kingdom ($2,854m sales)
(55) Lundbeck – Denmark ($2,824m sales)
(56) Samsung BioLogics – South Korea ($2,602m sales)
(57) Fosun International – China ($2,496m sales)
(58) Amneal Pharmaceuticals – United States ($2,361m sales)
(59) Joincare Pharmaceutical Group Industry Co., Ltd. – China ($2,353m sales)
(60) Lupin – India ($2,336m sales)
(61) Ferring Pharmaceuticals –Switzerland ($2,336m sales)
(62) United Therapeutics – United States ($2,328m sales)
(63) Zydus Lifesciences – India ($2,298m sales)
(64) Baxter International – United States ($2,249m sales)
(65) BioMarin Pharmaceutical – United States ($2,241m sales)
(66) BeiGene – China/Cayman Islands ($2,190m sales)
(67) Sumitomo Pharma – Japan ($2,169m sales)
(68) Gedeon Richter – Hungary ($2,117m sales)
(69) Recordati – Italy ($2,081m sales)
(70) Endo International – United States ($2,012m sales)
(71) Grünenthal Gruppe – Germany ($1,948m sales)
(72) Santen Pharmaceutical – Japan ($1,947m sales)
(73) Shandong Buchang Pharmaceuticals – China ($1,872m sales)
(74) Mallinckrodt – Ireland ($1,866m sales)
(75) Neurocrine Biosciences – United States ($1,861m sales)
(76) Swedish Orphan Biovitrum – Sweden ($1,783m sales)
(77) LEO Pharma – Denmark ($1,654m sales)
(78) Exelixis – United States ($1,629m sales)
(79) Krka Group – Slovenia ($1,589m sales)
(80) Towa Pharmaceutical – Japan ($1,579m sales)
(81) Alkem Laboratories – India ($1,496m sales)
(82) Shijiazhuang Yiling Pharmaceutical – China ($1,458m sales)
(83) CR Double-Crane Pharmaceuticals Co., Ltd. – China ($1,445m sales)
(84) Celltrion – South Korea ($1,435m sales)
(85) Meiji Holdings – Japan ($1,428m sales)
(86) Glenmark Pharmaceuticals – India ($1,414m sales)
(87) Alfasigma Group – Italy ($1,383m sales)
(88) Jiangsu Hansoh Pharmaceutical – China ($1,329m sales)
(89) Pierre Fabre – France ($1,303m sales)
(90) Biocon – India ($1,279m sales)
(91) Torrent Pharmaceuticals – India ($1,276m sales)
(92) Lantheus Holdings – United States ($1,263m sales)
(93) Mankind Pharma – India ($1,248m sales)
(94) Sawai Group Holdings – Japan ($1,224m sales)
(95) Livzon Pharmaceutical – China ($1,191m sales)
(96) Orion Pharmaceuticals – Finland ($1,176m sales)
(97) Zhejiang Huahai Pharmaceutical – China ($1,174m sales)
(98) Chong Kun Dang – South Korea ($1,163m sales)
(99) Zhejiang Medicine – China ($1,102m sales)
(100) Indivior – United States ($1,093m sales)
Explore the Top Pharma Companies with Outlook 2025
The top 100 rankings are collected as part of In Vivo’s Outlook 2025 report which includes industry rankings such as the Scrip 100, Generics Bulletin Top 50 and Scrip Asia 100.
As we look ahead to 2025, the pharmaceutical industry is poised for transformation once again. The increasing integration of AI across all facets of the industry is set to revolutionize drug discovery, development, patient care and commercialization.
Join us as we explore what 2025 has in store for pharma and medtech as these dynamic industries grow and confront global challenges.
Explore Outlook 2025 by taking a 1-week free trial today- find out more here.